Toward the development of podocyte-specific drugs

Kidney International

Volumn 77, Issue 8, 2010, Pages 662-668

  Reiser, Jochen ^a   Gupta, Vineet ^a   Kistler, Andreas D ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Glomerulopathy; Pathophysiology of renal disease and progression; Podocyte; Proteinuria; Renal protection

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCINEURIN INHIBITOR; CATHEPSIN L; COMPLEMENTARY DNA; CYCLOPEPTIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYNAMIN; GLUCOCORTICOID; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; ION CHANNEL; MEMBRANE RECEPTOR; NEPHRIN; NOTCH RECEPTOR; PROTEINASE; RNA; SHORT HAIRPIN RNA; SYNAPTOPODIN; TRANSFORMING GROWTH FACTOR BETA; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; VASCULOTROPIN A; VITRONECTIN RECEPTOR;

DISEASE COURSE; DRUG RESEARCH; DRUG TARGETING; GLOMERULOPATHY; GLOMERULUS; HIGH THROUGHPUT SCREENING; HUMAN; HYPERTENSION; KIDNEY; KIDNEY DISEASE; KIDNEY FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; SHORT SURVEY;

EID: 77950517549     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.559     Document Type: Short Survey

References (45)

1. Wiggins RC. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 2007; 71: 1205-1214.
2. Reiser J, Kriz W, Kretzler M et al. The glomerular slit diaphragm is a modified adherens junction. J Am Soc Nephrol 2000; 11: 1-8.
3. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 2006; 354: 1387-1401.
4. Shankland SJ, Pippin JW, Reiser J et al. Podocytes in culture: past, present, and future. Kidney Int 2007; 72: 26-36.
5. Benzing T. The promise of well-being: stay in shape with N(i)ck. J Am Soc Nephrol 2009; 20: 1425-1427.
6. Menne J, Meier M, Park JK et al. Nephrin loss in experimental diabetic nephropathy is prevented by deletion of protein kinase C alpha signaling in-vivo. Kidney Int 2006; 70: 1456-1462.
7. Uchida K, Suzuki K, Iwamoto M et al. Decreased tyrosine phosphorylation of nephrin in rat and human nephrosis. Kidney Int 2008; 73: 926-932.
8. Reiser J, von Gersdorff G, Loos M et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004; 113: 1390-1397.
9. Reiser J, Oh J, Shirato I et al. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem 2004; 279: 34827-34832.
10. Wei C, Moller CC, Altintas MM et al. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008; 14: 55-63.
11. Cheng HT, Kim M, Valerius MT et al. Notch2, but not Notch1, is required for proximal fate acquisition in the mammalian nephron. Development 2007; 134: 801-811.
12. Niranjan T, Bielesz B, Gruenwald A et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 2008; 14: 290-298.
13. Beck Jr LH, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21.
14. Reiser J, Polu KR, Moller CC et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 2005; 37: 739-744.
15. Winn MP, Conlon PJ, Lynn KL et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005; 308: 1801-1804.
16. Huber TB, Schermer B, Muller RU et al. Podocin and MEC-2 bind cholesterol to regulate the activity of associated ion channels. Proc Natl Acad Sci USA 2006; 103: 17079-17086.
17. Moller CC, Wei C, Altintas MM et al. Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol 2007; 18: 29-36.
18. Schiffer M, Bitzer M, Roberts IS et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001; 108: 807-816.
19. Yamamoto T, Nakamura T, Noble NA et al. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993; 90: 1814-1818.
20. Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716.
21. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136.
22. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
23. Barrett AJ, Kirschke H. Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol 1981; 80(Part C): 535-561.
24. Sever S, Altintas MM, Nankoe SR et al. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest 2007; 117: 2095-2104.
25. Lohmuller T, Wenzler D, Hagemann S et al. Toward computer-based cleavage site prediction of cysteine endopeptidases. Biol Chem 2003; 384: 899-909.
26. Faul C, Donnelly M, Merscher-Gomez S et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14: 931-938.
27. An WF, Tolliday NJ. Introduction: cell-based assays for high-throughput screening. Methods Mol Biol. 2009, 486; 1-12.
28. Mundel P, Reiser J, Zuniga Mejia Borja A et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248-258.
29. Saleem MA, O'Hare MJ, Reiser J et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 2002; 13: 630-638.
30. Drummond IA. Kidney development and disease in the zebrafish. J Am Soc Nephrol 2005; 16: 299-304.
31. Weavers H, Prieto-Sánchez S, Grawe F et al. The insect nephrocyte is a podocyte-like cell with a filtration slit diaphragm. Nature 2009; 457: 322-326.
32. Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 2005; 4: 35-44.
33. Mundel P, Reiser J, Kriz W. Induction of differentiation in cultured rat and human podocytes. J Am Soc Nephrol 1997; 8: 697-705.
34. Faul C, Asanuma K, Yanagida-Asanuma E et al. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 2007; 17: 428-437.
35. Yamauchi K, Takano Y, Kasai A et al. Screening and identification of substances that regulate nephrin gene expression using engineered reporter podocytes. Kidney Int 2006; 70: 892-900.
36. Mayer G, Boileau G, Bendayan M. Furin interacts with proMT1-MMP and integrin alphaV at specialized domains of renal cell plasma membrane. J Cell Sci 2003; 116: 1763-1773.
37. Reiser J, Mundel P. Dual effects of RAS blockade on blood pressure and podocyte function. Curr Hypertens Rep 2007; 9: 403-408.
38. Ransom RF, Lam NG, Hallett MA et al. Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int 2005; 68: 2473-2483.
39. Kajiyama H, Titus S, Austin CP et al. Tetracycline-inducible gene expression in conditionally immortalized mouse podocytes. Am J Nephrol 2009; 29: 153-163.
40. Morris MC, Deshayes S, Heitz F et al. Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol Cell 2008; 100: 201-217.
41. Ina K, Kitamura H, Tatsukawa S et al. Glomerular podocyte endocytosis of the diabetic rat. J Electron Microsc (Tokyo) 2002; 51: 275-279.
42. Eyre J, Ioannou K, Grubb BD et al. Statin-sensitive endocytosis of albumin by glomerular podocytes. Am J Physiol Renal Physiol 2007; 292: F674-F681.
43. Akilesh S, Huber TB, Wu H et al. Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci USA 2008; 105: 967-972.
44. Dechantsreiter MA, Planker E, Matha B et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 1999; 42: 3033-3040.
45. Xiong JP, Stehle T, Zhang R et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002; 296: 151-155.